Contraindications: When Stem Cell Therapy Is Not Indicated

Contraindications, in the regenerative-medicine register, are the questions a careful consultation answers before the harvest is scheduled — and the rooms one trusts are the rooms that ask them in full. The shorthand is misleadingly simple: malignancy, autoimmune flare, infection, pregnancy. The longer reading is more textured. Some exclusions are absolute; some are deferrals; some are relative cautions that reframe rather than withdraw. 講真嘅, the editorial honesty separates the careful Seoul operators from the marketing copy. A patient told plainly that they are not currently a candidate has been served well.

What contraindication actually means in autologous regenerative medicine

Contraindication, in the regenerative-medicine consultation, is a stratified concept rather than a binary one — and the strata correspond to different consultation outcomes. An absolute contraindication is a clinical state in which the procedure is, on the current evidence, not offered: active malignancy, an active autoimmune flare, current pregnancy or lactation, an active infection at the harvest or injection site, or a clotting disorder that cannot be safely managed around the harvest. A relative contraindication is a clinical state in which the procedure may be deferred, modified, or proceeded with under tighter pre-procedural workup: a history of malignancy outside the prudent window, a stable but treated autoimmune condition, anticoagulant therapy that can be safely paused, an unstable chronic condition awaiting optimisation. A reframing contraindication is a clinical state in which the patient's indication is, on consideration, better served by an adjacent regenerative pathway — bone-marrow MSCs rather than adipose SVF in some orthopaedic settings, platelet-rich plasma rather than cell therapy in some dermatological ones, or no procedure at all in indications for which the evidence base does not yet support intervention. The careful clinic walks the patient through which stratum applies, and why. The rooms one returns to are the rooms in which the operator is willing to say, plainly, that today is not the day. The vocabulary itself rewards reading carefully. The phrase not a candidate is, in the editorial register the more rigorous Korean operators use, neither a refusal nor a setback. It is a clinical position that may evolve — with treatment of the underlying condition, with the passage of a deferral window, or with the patient's reconsideration of indication. The conservative position the field takes is that the patient most poorly served is the patient who is treated despite a relative contraindication that should have been addressed first.

Absolute contraindications — when the procedure is not offered

The absolute contraindications are the shortest section of the consultation paperwork and the most consequential. Active malignancy of any kind, regardless of stage or location, is treated as an absolute contraindication in the careful Seoul practices — the theoretical concern is that the paracrine signalling environment favourable to wound repair is, in principle, also favourable to the survival and progression of latent or active malignant cells, and the conservative editorial position is that the field's evidence base does not yet support proceeding while malignancy is active. Pregnancy and lactation are treated as absolute contraindications across the published literature; the procedure is deferred to a window after the conclusion of breastfeeding, with the timing individualised by indication. An active infection at the planned harvest site or injection site is an absolute contraindication for the duration of the infection; the procedure is rescheduled once the infection has resolved and a suitable interval has elapsed. An uncontrolled bleeding disorder, or anticoagulant therapy that cannot be safely paused for the harvest window under the supervision of the prescribing physician, is an absolute contraindication on procedural grounds — the harvest itself is a small surgical intervention, and the inability to manage haemostasis carries risk that the cells cannot offset. An active autoimmune flare — defined as clinically meaningful disease activity rather than a stable, treated background condition — is an absolute contraindication for the duration of the flare; the procedure is deferred until the disease is quiescent and the patient's rheumatologist or relevant specialist concurs with the proposed timing. A 2020 review in Cell Transplantation summarised the contraindication framework across published autologous stem cell protocols and converged on a comparable list, with the literature consistently emphasising that the absolute contraindications are exclusions on safety grounds rather than restrictions on access — and that the deferral window in most cases is genuinely a deferral rather than a permanent exclusion. The careful clinic frames this distinction up front.

Relative contraindications — the deferrals and the closer workups

The relative contraindications are the longer and more nuanced section of the consultation, and they reward an unhurried conversation. A personal history of malignancy outside the prudent five-year window is treated, in most Korean practices, as a relative rather than an absolute contraindication — a multidisciplinary review with the patient's oncologist is the standard, with the conversation focused on the specific cancer history, the surveillance milestones, and the treating clinician's assessment of remission stability. A treated, stable autoimmune condition — Hashimoto's thyroiditis with established euthyroidism, a quiescent inflammatory bowel condition under maintenance therapy, controlled rheumatoid arthritis on stable disease-modifying medication — is generally not an absolute exclusion in the Seoul rooms one trusts, but warrants pre-procedural review with the relevant specialist and a candid discussion of the theoretical signalling considerations. Diabetes mellitus, hypertension, and dyslipidaemia are typically treated as conditions to be optimised rather than as exclusions; the consultation requests recent blood work, current medication regimens, and a brief targeted physical examination, with the procedure proceeding under standard pre-operative principles. Anticoagulant therapy that can be safely paused for a defined window before and after the harvest, under the supervision of the prescribing physician, is a relative rather than an absolute contraindication; the careful clinic coordinates directly with the prescriber rather than asking the patient to navigate the pause alone. A history of keloid scarring or unusual wound healing patterns is a relative caution that may inform the harvest-site selection and the dressing protocol rather than the procedure itself. Significant psychiatric instability, or unrealistic expectations identified during the consultation, are treated as deferral grounds in the more thoughtful practices — the procedure is best offered to a patient who has had time to read the hedged claims and consent to the realistic outcome envelope rather than to the marketing one. The relative-contraindication conversation, in its honest form, takes longer than the absolute-contraindication one. That is the right cadence.

Indication-specific cautions — when the cells are not the right tool

Some indications are not contraindicated on patient-safety grounds but are, on closer reading, better served by an adjacent regenerative pathway or by no intervention at all — and the careful operator names these cases without hesitation. Severe established osteoarthritis with bone-on-bone changes is, in the orthopaedic literature, an indication in which adipose SVF and ADSC preparations are unlikely to deliver the structural change the patient is hoping for; the conversation is more honest when the operator names the limit and refers the patient to the relevant orthopaedic surgical pathway. Profound, established skin atrophy — for example, the textural changes that accompany advanced photoageing or long-standing topical-corticosteroid use — is similarly a setting in which the cell-based pathway is unlikely to produce the result the patient is hoping for, and in which a layered protocol of energy-based and structural interventions is, on the evidence, the better answer. Acute neurological injury, despite the considerable interest the regenerative-medicine literature has shown in this space, remains an indication in which the published evidence is preliminary and in which the prudent editorial position is that the procedure is best offered within registered clinical trials rather than in the routine clinical setting. The aesthetic indications most poorly served by the cell-based pathway are those for which a faster and better-validated structural intervention exists — toxin or filler for a specific dynamic or volume concern, energy-based skin tightening for a specific laxity, or surgical refinement for a structural one. The cell-based pathway is most useful where the indication is one of tissue compliance, mild post-acne textural change, or modest aesthetic refinement in a patient whose expectation has been carefully calibrated. The honest editorial framing is that autologous regenerative medicine is a particular tool for a particular set of indications, used best in a clinical room willing to name the cases for which it is not the answer. The room willing to name those cases is the room one returns to. A patient considering an adjacent indication may find a fuller mapping in our long-form companion piece on the [adipose-derived SVF preparation](/adipose-derived-svf-explained/) and the [bone-marrow MSC pathway](/bone-marrow-mesenchymal-stem-cells/) — which together cover the principal preparations the Seoul rooms work with.

The contraindication checklist — what the consultation should cover

The careful consultation runs, in our reading of the more rigorous Seoul practices, a recognisable contraindication checklist — and a thoughtful patient is welcome to bring the same checklist to the room and read it alongside the operator. The checklist below is a synthesis drawn from a year of clinic visits across Cheongdam and Apgujeong, from the published consensus literature, and from the consent paperwork the more transparent practices share with prospective patients. The list is descriptive, not exhaustive; the consultation, not the article, is the appropriate place for the patient's specific clinical state to be assessed.

When the answer is yes — what the green-light consultation looks like

A green-light consultation has, in our reading, a recognisable cadence — and the cadence is as informative as the conclusion. The careful operator works through the contraindication list aloud rather than silently, names which categories the patient has cleared and on what grounds, and identifies any relative cautions that warrant brief pre-procedural workup. The conversation moves to the indication, with a frank discussion of the evidence base, the realistic outcome envelope, and the protocol the clinic proposes; the consent paperwork is reviewed in the same unhurried register, with the operator available to expand any clause the patient finds opaque. The pre-procedural workup, where indicated, is arranged in coordination with the patient's other clinicians rather than left for the patient to navigate alone. The harvest is scheduled with adequate time after the workup, with the patient given a written summary of the contraindications reviewed, the relative cautions noted, and any specific medication adjustments to be made in the days surrounding the procedure. The aftercare schedule, the warning signs, and the direct after-hours contact are explained before the patient leaves the consultation, not on the day of the harvest. The Korean Ministry of Health and Welfare's [foreign-patient registration framework](https://www.mohw.go.kr/eng/) — registration A-2026-04-02-06873, in our case — is the regulatory baseline for treating international patients, and a careful guest understands that the green light is, properly, a clinical conclusion shaped by both the contraindication review and the indication review. The room one returns to is the room in which both reviews are conducted with equal care. The room one declines is the room in which either is rushed.

What to bring to the consultation — the practical checklist

A consultation that runs efficiently is, in our reading, one in which the patient has arrived with the documentation the careful operator will want to see — and a thoughtful clinic asks for these in advance. A current medication list, with doses and prescribing physicians, is the foundation; the list should include over-the-counter medications, herbal supplements, and any high-dose vitamin protocols. Recent blood work — within six months in most practices — covering a complete blood count, basic metabolic panel, coagulation indices, and any indication-specific markers is typically requested. A recent imaging study relevant to the indication, where one exists, is welcome; the orthopaedic consultations work better with current imaging rather than older studies. A summary of the patient's medical history, prepared in advance, is more efficient than reconstructing it during the consultation; the summary should cover any significant illnesses, surgeries, hospitalisations, allergies, family history of malignancy or autoimmunity, and the current contact details for the patient's primary clinician. For international patients arriving from outside Korea, a translated summary or a clinical-letter style document is preferred to fragmented records; the careful Seoul rooms can work with English, Cantonese, Mandarin, Japanese, or Korean documentation, and translation arrangements can be made in advance for other languages. The patient is also welcome to arrive with their own questions written down — what the operator's complication rate is, what the in-house deferral threshold is, what the proposed protocol is, what the realistic outcome envelope looks like for the specific indication. The consultation that proceeds well is the one in which the patient is, quietly, the more prepared party.

“A patient who is told plainly, in the first thirty minutes, that they are not currently a candidate has been served better than a patient who is treated despite the qualification. The contraindication checklist is not the procedure's gatekeeper; it is its first diagnostic.”

Liu Mei-Hua, on the editorial role of the consultation

Frequently asked questions

Does a personal cancer history mean I can never have stem cell therapy?

Not necessarily — and the conversation is genuinely individualised. Active malignancy is an absolute contraindication; a history within the previous five years is typically treated as a deferral pending multidisciplinary review with the patient's oncologist; a history beyond five years is generally a relative contraindication that warrants indication-specific review and a candid discussion of the theoretical signalling considerations. The conservative editorial position is that the field's longer-tail data does not yet support proceeding lightly in this setting. A careful consultation will request the oncology summary directly.

I have an autoimmune condition. Am I automatically excluded?

Active autoimmune flares are absolute contraindications for the duration of the flare. Stable, well-controlled autoimmune conditions — Hashimoto's thyroiditis with established euthyroidism, treated rheumatoid arthritis on stable medication, quiescent inflammatory bowel disease — are typically treated as relative contraindications rather than as absolute exclusions, with a pre-procedural review by the relevant specialist and a candid discussion of the theoretical signalling considerations. The room one trusts is the room willing to coordinate directly with the patient's existing specialists.

Can I have stem cell therapy if I am on blood thinners?

Often yes, with planning. Anticoagulant and antiplatelet therapies are typically reviewed with the prescribing physician, with the medication paused for a defined window before and after the harvest under that physician's supervision. The careful Seoul rooms coordinate this pause directly with the prescriber rather than asking the patient to navigate it alone. Anticoagulant therapy that cannot be safely paused — because of a recent thromboembolic event or a high-risk indication — is treated as an absolute contraindication on procedural grounds.

What about pregnancy and breastfeeding?

Both are absolute contraindications. The procedure is deferred until after the conclusion of pregnancy and the conclusion of lactation, with the timing individualised by indication and by the patient's preference. The careful clinic does not negotiate this deferral; the conversation moves to scheduling for an appropriate window after weaning. Patients who become unexpectedly pregnant between the consultation and the scheduled harvest should notify the clinic; the procedure is rescheduled rather than abandoned.

Are there age limits for autologous stem cell therapy?

Not formal ones in most Korean practices, but practical considerations apply at both ends of the age range. Younger patients — broadly under 25 — are usually screened for whether the indication itself is appropriate, given that several of the conditions the procedure addresses are uncommon in that group. Older patients are screened for the standard cardiovascular, oncological, and haematological considerations relevant to the harvest itself, and for the realistic outcome envelope given underlying tissue quality. Age in itself is rarely the determining factor; clinical state and indication are.

I have diabetes. Does that exclude me?

Uncontrolled diabetes is a relative contraindication that warrants optimisation of glycaemic control before the procedure; well-controlled diabetes is generally not an exclusion. The consultation will request recent blood work — including HbA1c — and may liaise with the patient's diabetes care team. Wound healing at the donor site is a particular consideration in this setting, with the careful operator emphasising the dressing protocol and the early follow-up schedule. A frank conversation about realistic outcomes in the indication being treated is part of the standard consultation.

What if the consultation identifies an issue I was not aware of?

The careful Seoul operators treat unexpected findings — a previously undiagnosed cardiac murmur, an unusual blood-test result, a borderline imaging finding — as a reason to pause the procedure pathway and refer the patient appropriately. The patient leaves the consultation with the relevant referral, a clear summary of the finding, and an open invitation to return once the issue has been worked up. This pathway is, in our reading, the editorial signal of a careful clinic; the rooms that minimise unexpected findings to keep the procedure on schedule are the rooms one declines.